{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:35:47Z","timestamp":1790166947844,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bbr.2020.113098","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T20:19:01Z","timestamp":1610050741000},"page":"113098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia"],"prefix":"10.1016","volume":"402","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1965-9484","authenticated-orcid":false,"given":"Kazunari","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2020.113098_bib0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2020.113098_bib0010","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2020.113098_bib0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13066","article-title":"Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies","volume":"140","author":"Papola","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbr.2020.113098_bib0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1192\/apt.bp.115.014928","article-title":"Management of antipsychotic-induced hyperprolactinaemia","volume":"23","author":"Gupta","year":"2017","journal-title":"Bjpsych Adv."},{"key":"10.1016\/j.bbr.2020.113098_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40263-014-0222-y","article-title":"Seizure associated with clozapine: incidence, etiology, and management","volume":"29","author":"Williams","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2020.113098_bib0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/JCP.0b013e31819a91f1","article-title":"Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs","volume":"29","author":"Ozbilen","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40263-016-0352-5","article-title":"Antipsychotic drug-induced somnolence: incidence, mechanisms, and management","volume":"30","author":"Fang","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2020.113098_bib0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0050","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1017\/S0033291717000873","article-title":"Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis","volume":"47","author":"Vermeulen","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbr.2020.113098_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","article-title":"Influence of antipsychotics on mortality in schizophrenia: systematic review","volume":"113","author":"Weinmann","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2020.113098_bib0060","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0065","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaa063","article-title":"Antipsychotic dose in acute schizophrenia: a meta-analysis","author":"Takeuchi","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2020.113098_bib0070","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2020.113098_bib0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hup.1275","article-title":"No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics","volume":"27","author":"Yasui-Furukori","year":"2012","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hup.1218","article-title":"Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia","volume":"26","author":"Suzuki","year":"2011","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.bbr.2020.113098_bib0085","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1176\/appi.ajp.2010.09070937","article-title":"Processing speed deficits in schizophrenia: reexamining the evidence","volume":"167","author":"Knowles","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0090","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/YIC.0b013e32832d6c18","article-title":"Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans affairs population","volume":"24","author":"Duncan","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia","volume":"184","author":"Meaney","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/0272989X19856884","article-title":"Bayesian meta-analysis of multiple continuous treatments with individual participant-level data: an application to antipsychotic drugs","volume":"39","author":"Spertus","year":"2019","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.bbr.2020.113098_bib0105","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12284","article-title":"Exposure to second-generation antipsychotics and risk of type 2 diabetes mellitus in adolescents and young adults: a nationwide study in Taiwan","volume":"80","author":"Tu","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbr.2020.113098_bib0115","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/schbul\/sbu164","article-title":"Antipsychotic treatment and mortality in schizophrenia","volume":"41","author":"Torniainen","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2020.113098_bib0120","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2020.113098_bib0125","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2020.113098_bib0130","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an update","volume":"57","author":"Mauri","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbr.2020.113098_bib0135","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.4088\/JCP.16m11049","article-title":"Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the cura\u00e7ao extrapyramidal syndromes study XII","volume":"78","author":"Mentzel","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0140","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","article-title":"Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring","volume":"120","author":"Sparshatt","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbr.2020.113098_bib0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0b013e3182126d83","article-title":"Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?","volume":"33","author":"Seto","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bbr.2020.113098_bib0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hup.2393","article-title":"Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia","volume":"29","author":"Suzuki","year":"2014","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.bbr.2020.113098_bib0155","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/NDT.S30767","article-title":"Treatment of neurolept-induced tardive dyskinesia","volume":"9","author":"Jankelowitz","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bbr.2020.113098_bib0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12883-019-1385-4","article-title":"Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis","volume":"19","author":"Patterson-Lomba","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.bbr.2020.113098_bib0165","article-title":"Antipsychotic reduction and\/or cessation and antipsychotics as specific treatments for tardive dyskinesia","volume":"2","author":"Bergman","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bbr.2020.113098_bib0170","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0706743719828968","article-title":"Treatment recommendations for tardive dyskinesia","volume":"64","author":"Ricciardi","year":"2019","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics\u2014a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.bbr.2020.113098_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2020.04.031","article-title":"Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis","author":"Labad","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2020.113098_bib0185","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/acps.12313","article-title":"A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia","volume":"130","author":"Stubbs","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbr.2020.113098_bib0190","doi-asserted-by":"crossref","first-page":"238","DOI":"10.9758\/cpn.2016.14.3.238","article-title":"Effects of antipsychotics on bone mineral density in patients with schizophrenia: gender differences","volume":"14","author":"Chen","year":"2016","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.bbr.2020.113098_bib0195","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2016.1167873","article-title":"Relationship between antipsychotic medication, serum prolactin levels and osteoporosis\/osteoporotic fractures in patients with schizophrenia: a critical literature review","volume":"15","author":"De Hert","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bbr.2020.113098_bib0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","article-title":"Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia","volume":"22","author":"O\u2019Keane","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hup.2387","article-title":"Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study","volume":"29","author":"Wang","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0210","doi-asserted-by":"crossref","first-page":"333","DOI":"10.9758\/cpn.2019.17.3.333","article-title":"Serum prolactin and bone mineral density in schizophrenia: a systematic review","volume":"17","author":"Lally","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.bbr.2020.113098_bib0215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/713847170","article-title":"Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study","volume":"29","author":"Bobes","year":"2003","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.bbr.2020.113098_bib0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41537-018-0053-9","article-title":"Risk of weight gain for specific antipsychotic drugs: a meta-analysis","volume":"4","author":"Spertus","year":"2018","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.bbr.2020.113098_bib0225","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0235","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","article-title":"Treatment with antipsychotics and the risk of diabetes in clinical practice","volume":"197","author":"Kessing","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0240","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0245","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-244X-11-197","article-title":"Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?","volume":"11","author":"Ulcickas Yood","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0250","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.4088\/JCP.14m08996","article-title":"Incident users of antipsychotic agents and future use of cholesterol-lowering drugs: an observational, pharmacoepidemiologic study","volume":"76","author":"Skrede","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0255","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00023210-200418090-00005","article-title":"Dose response and atypical antipsychotics in schizophrenia","volume":"18","author":"Kinon","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2020.113098_bib0260","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/CIRCULATIONAHA.114.008779","article-title":"Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study","volume":"130","author":"Lin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.bbr.2020.113098_bib0265","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/acps.12345","article-title":"Antipsychotic exposure prior to acute myocardial infarction in patients with serious mental illness","volume":"131","author":"Wu","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbr.2020.113098_bib0270","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JCP.0b013e3182900dfe","article-title":"Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study","volume":"33","author":"Hsieh","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0275","doi-asserted-by":"crossref","DOI":"10.2174\/1570161118666200211114656","article-title":"Antipsychotic drugs and risk of developing venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis","author":"Arasteh","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0280","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/pds.2210","article-title":"Antipsychotic drugs and risk of pulmonary embolism","volume":"21","author":"Allenet","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bbr.2020.113098_bib0285","doi-asserted-by":"crossref","first-page":"c4245","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","volume":"341","author":"Parker","year":"2010","journal-title":"BMJ."},{"key":"10.1016\/j.bbr.2020.113098_bib0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148212","article-title":"Star network investigators, antipsychotic dose mediates the association between polypharmacy and corrected QT interval","volume":"11","author":"Barbui","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2020.113098_bib0295","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40263-014-0196-9","article-title":"QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review","volume":"28","author":"Hasnain","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2020.113098_bib0300","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2020.113098_bib0305","first-page":"1","article-title":"Plasma concentrations of antipsychotics and QTc prolongation: a pilot study","author":"H\u00f8imark","year":"2020","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0310","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/11591710-000000000-00000","article-title":"Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management","volume":"25","author":"Gugger","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2020.113098_bib0315","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases","volume":"69","author":"Palmer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0320","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/YIC.0b013e32805b71a3","article-title":"Dose-dependent constipation with higher doses of quetiapine: a case series","volume":"22","author":"Raedler","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0325","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/sbq137","article-title":"Risk factors for ileus in patients with schizophrenia","volume":"38","author":"Nielsen","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2020.113098_bib0330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.schres.2017.10.024","article-title":"Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: a retrospective cohort study","volume":"195","author":"Chen","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2020.113098_bib0335","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/NMD.0b013e31824cb359","article-title":"Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics","volume":"200","author":"Torniainen","year":"2012","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.bbr.2020.113098_bib0340","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jpsychires.2012.02.013","article-title":"The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients","volume":"46","author":"Hori","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbr.2020.113098_bib0345","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/0269881108100777","article-title":"Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder","volume":"24","author":"Elie","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0350","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1017\/S0033291708004558","article-title":"Working memory in schizophrenia: a meta-analysis","volume":"39","author":"Forbes","year":"2009","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbr.2020.113098_bib0355","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","article-title":"A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects","volume":"89","author":"Woodward","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2020.113098_bib0360","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fpsyt.2018.00447","article-title":"Dose reduction\/discontinuation of antipsychotic drugs in psychosis; effect on cognition and functional outcomes","volume":"9","author":"Omachi","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eurpsy.2011.02.003","article-title":"The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis","volume":"27","author":"Faber","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0370","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/schbul\/sbt090","article-title":"Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study","volume":"39","author":"Takeuchi","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2020.113098_bib0375","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/0269881118756062","article-title":"Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study","volume":"32","author":"Zhou","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0380","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","article-title":"Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials","volume":"45","author":"Tani","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2020.113098_bib0385","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2045125311405566","article-title":"Clozapine-related EEG changes and seizures: dose and plasma-level relationships","volume":"1","author":"Varma","year":"2011","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0390","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0004867412438871","article-title":"A review of the use of clozapine levels to guide treatment and determine cause of death","volume":"46","author":"Stark","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0395","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2020.113098_bib0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/pcn.12640","article-title":"Zotepine-induced convulsion at a low dose in a case of paranoid schizophrenia","volume":"72","author":"Ali","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbr.2020.113098_bib0405","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/0253-7613.106447","article-title":"Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia","volume":"45","author":"Khairkar","year":"2013","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0410","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1345\/aph.1P761","article-title":"Current treatment strategies for clozapine-induced sialorrhea","volume":"45","author":"Bird","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bbr.2020.113098_bib0415","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/2045125316641019","article-title":"Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life","volume":"6","author":"Maher","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0420","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/0269881118795333","article-title":"Antipsychotic drug use and pneumonia: systematic review and meta-analysis","volume":"32","author":"Dzahini","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0425","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/schbul\/sbr202","article-title":"Second-generation antipsychotic medications and risk of pneumonia in schizophrenia","volume":"39","author":"Kuo","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2020.113098_bib0430","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1532-5415.2011.03853.x","article-title":"Comparative safety of antipsychotic medications in nursing home residents","volume":"60","author":"Huybrechts","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.bbr.2020.113098_bib0435","doi-asserted-by":"crossref","first-page":"418","DOI":"10.7326\/0003-4819-152-7-201004060-00006","article-title":"Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case--control study","volume":"152","author":"Trifiro","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bbr.2020.113098_bib0440","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4088\/JCP.14m09301","article-title":"Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study","volume":"77","author":"Hung","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0445","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/npr2.12034","article-title":"Risk factors for pneumonia in patients with schizophrenia","volume":"38","author":"Haga","year":"2018","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.bbr.2020.113098_bib0450","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.euroneuro.2013.04.002","article-title":"Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis","volume":"23","author":"S\u00f8rensen","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0455","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.4088\/JCP.14m09098","article-title":"Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: a 10-year population-based case-control study","volume":"76","author":"Wu","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.bbr.2020.113098_bib0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hup.917","article-title":"Haematological toxicity of drugs used in psychiatry","volume":"23","author":"Flanagan","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.113098_bib0465","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.pnpbp.2007.03.009","article-title":"High clozapine concentrations in leukocytes in a patient who developed leukocytopenia","volume":"31","author":"Bergemann","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0470","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.152.4.610","article-title":"Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites","volume":"152","author":"Centorrino","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0475","doi-asserted-by":"crossref","first-page":"413","DOI":"10.9758\/cpn.2017.15.4.413","article-title":"Neutropenia with multiple antipsychotics including dose dependent neutropenia with lurasidone","volume":"15","author":"Sood","year":"2017","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.bbr.2020.113098_bib0480","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajp.2017.05.004","article-title":"Neuroleptic malignant syndrome: a neuro-psychiatric emergency: recognition, prevention, and management","volume":"29","author":"Velamoor","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.bbr.2020.113098_bib0485","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/1060028016657553","article-title":"Neuroleptic malignant syndrome","volume":"50","author":"Pileggi","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bbr.2020.113098_bib0490","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/070674371205700810","article-title":"Neuroleptic malignant syndrome-an 11-year longitudinal case-control study","volume":"57","author":"Nielsen","year":"2012","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0495","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0447.2003.02385.x","article-title":"Risk factors in neuroleptic malignant syndrome. A case-control study","volume":"107","author":"Viejo","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbr.2020.113098_bib0500","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1176\/ajp.154.8.1156","article-title":"Case-control study of neuroleptic malignant syndrome","volume":"154","author":"Sachdev","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0505","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome. A case-control study","volume":"46","author":"Keck","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0510","doi-asserted-by":"crossref","first-page":"e1752","DOI":"10.1097\/MD.0000000000001752","article-title":"A case report of catatonia and neuroleptic malignant syndrome with multiple treatment modalities: short communication and literature review","volume":"94","author":"Chiou","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.bbr.2020.113098_bib0515","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.pra.0000265770.17871.01","article-title":"Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis","volume":"13","author":"Evcimen","year":"2007","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.bbr.2020.113098_bib0520","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.schres.2009.12.029","article-title":"Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study","volume":"117","author":"De Hert","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2020.113098_bib0525","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bbr.2020.113098_bib0530","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbr.2020.113098_bib0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2018.11.030","article-title":"An investigation into the relationship between clozapine treatment and cognitive performance in patients with treatment resistant schizophrenia","author":"McArdle","year":"2019","journal-title":"Schizophrenia"},{"key":"10.1016\/j.bbr.2020.113098_bib0540","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psychres.2017.10.010","article-title":"Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients","volume":"258","author":"Molins","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbr.2020.113098_bib0545","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.2015.14050673","article-title":"Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine","volume":"172","author":"Rajji","year":"2015","journal-title":"Am. J. Psychiatry"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643282030797X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643282030797X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:26:59Z","timestamp":1759066019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016643282030797X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":109,"alternative-id":["S016643282030797X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2020.113098","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2020.113098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113098"}}